Japan PCSK9 Rivalry Builds As Praluent Edges Closer To Market
This article was originally published in PharmAsia News
Executive Summary
Sanofi's Praluent looks set to become the second PCSK9 inhibitor available in Japan following a new recommendation for approval, but can it hold its own against launched rival Repatha? Meanwhile, AstraZeneca’s Brilinta is facing a delay.
You may also be interested in...
Sanofi Reaches For Post-Plavix Growth In Japan
While Sanofi’s Japanese pharma business is feeling the impact of generic competition to its former blockbuster top product, it is aiming to move back into growth through a string of planned launches over the next few years.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Genmab buys into ADCs; Roivant set to take on AbbVie in uveitis; Ipsen signs firs ADC pact; South Korea looks to build biotech momentum; and the end of the road for Acorda.